1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

  • January 2017
  • -
  • Delve Insight

Summary

Table of Contents


DelveInsight’s Report, “Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Report is to understand the market and pipeline status of the drugs around the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
- A review of the marketed products under prescription for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs.
- Coverage of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy:
- Evaluate the marketing status and exclusivity details of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
- API intelligence over marketed drugs forMetastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancerand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer.
- Uncovering opportunities in the rapidly growing US market.

Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Hormone Replacement Therapy Market - Growth, Trends and Forecast (2017 - 2022)

Global Hormone Replacement Therapy Market - Growth, Trends and Forecast (2017 - 2022)

  • $ 4250
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The Global market for Hormone Replacement Therapy (HRT) Market is expected to reach $XX by the end of 2020 growing at a CAGR of around XX% from 2015 to 2021. Hormone Replacement therapy is the management ...

Breast Cancer Treatment Drug Markets in China

Breast Cancer Treatment Drug Markets in China

  • $ 4000
  • Industry report
  • March 2017
  • by Asia Market Information & Development Company

China’s demand for Breast Cancer Treatment Drug has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high ...

Prostate Cancer Treatment Drugs Markets in China

Prostate Cancer Treatment Drugs Markets in China

  • $ 4000
  • Industry report
  • March 2017
  • by Asia Market Information & Development Company

China’s demand for Prostate Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a ...


Download Unlimited Documents from Trusted Public Sources

Insulin Market and Diabetes Statistics in the US

  • March 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Hormone and Therapy Market in Pakistan and the US

  • March 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Therapy Market - Forecast

  • March 2017
    9 pages
  • Diabetes  

  • United States  

    Europe  

    Japan  

View report >

Related Market Segments :

Hormone
Prostate Cancer

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.